Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart Cafraglutide in Overweight or Obesity After Switching From GLP-1RA
NCT07908316Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Nov 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of maridebart cafraglutide in obesity (6 cohorts), sponsored by Amgen. Primary endpoints: Area Under the Plasma Concentration-time Curve Over a Dosing Interval up to 115 days and Maximum Observed Plasma Concentration up to 115 days. Started Nov 2026; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07908316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07908316.